Low-Dose Naltrexone and Levothyroxine Interaction: What Patients and Prescribers Need to Know

Can you take low-dose naltrexone and levothyroxine together?

Naltrexone (as low-dose naltrexone, or LDN, a compounded off-label preparation) and levothyroxine (T4 thyroid hormone replacement) do not share a metabolic pathway, transporter, or protein-binding site that would predict a clinically meaningful direct interaction. Levothyroxine is not metabolized by cytochrome P450 enzymes; it is deiodinated peripherally and conjugated via sulfation and glucuronidation. Naltrexone at standard 50 mg doses is not a clinically significant inhibitor or inducer of major CYP isoforms, and LDN doses are roughly 10-fold lower still. No controlled pharmacokinetic study of the LDN-levothyroxine pair specifically has been identified in this review.

The reason this combination still gets flagged for monitoring is indirect and pharmacodynamic, not pharmacokinetic. LDN is used off-label, often for autoimmune or chronic pain conditions, on the theory that transient nightly opioid-receptor blockade triggers a rebound in endogenous opioid peptides that modulates immune signaling. If a patient's hypothyroidism is caused by Hashimoto thyroiditis, an autoimmune process, and LDN meaningfully dampens that autoimmune activity, the thyroid gland could regain some function, and a previously stable levothyroxine dose could become too high. This is a plausible mechanism, not an established clinical outcome, and it is the correct thing to track rather than the drug pairing itself.

What is actually established, and what is not

Levothyroxine absorption is well documented to be sensitive to fasting state, gastric pH, and concurrent medications generally, which is why the standard clinical guidance is to take it on an empty stomach and separate it from other oral drugs by at least 30 to 60 minutes. That guidance is a general levothyroxine-handling principle, not something specific to naltrexone. LDN carries no known absorption-competition risk with levothyroxine, and the two are typically dosed roughly 8 or more hours apart in practice (levothyroxine in the morning, LDN at bedtime), which resolves any theoretical timing concern without requiring a special protocol.

What is not established is any quantified rate at which LDN reduces levothyroxine requirements, how often that occurs, or how large the antibody or dose changes tend to be. Small open-label pilot studies and narrative reviews have reported reductions in thyroid peroxidase antibody titers and case-level need for levothyroxine dose reduction in Hashimoto thyroiditis patients started on LDN, but these studies are small, frequently unblinded, and not designed to establish a reliable effect size. Specific numeric outcomes from this literature should be treated as unverified until confirmed against the primary paper, and this article intentionally does not repeat precise percentages or titer values that cannot be sourced with confidence here.

Naltrexone (as Vivitrol, the FDA-approved extended-release injectable) carries an explicit prescribing-information warning against use with opioid agonists, since naltrexone will block or reverse opioid analgesic and euphoric effects at any formulation or dose (per naltrexone prescribing information). That is the highest-severity interaction in the LDN interaction profile generally, and it is unrelated to levothyroxine. Levothyroxine's own labeling describes absorption as reduced by malabsorption states and by co-administration with agents such as calcium carbonate, iron salts, proton-pump inhibitors, and cholestyramine (per levothyroxine prescribing information); naltrexone is not on that list, and no compounded LDN excipient has been documented in the literature reviewed here to interfere with levothyroxine absorption when doses are separated by hours as is typical practice.

Evidence-status assessment: LDN plus levothyroxine

Why timing still matters even without a direct interaction

Levothyroxine's narrow absorption window is a general property of the drug, not a property of this specific pairing. Most patients who take levothyroxine first thing in the morning on an empty stomach and take LDN at bedtime are already separated by 8 or more hours, which is well beyond the 30- to 60-minute separation typically recommended for other oral medications and levothyroxine. Patients who take LDN earlier in the day, or who take levothyroxine at night, should still apply the standard separation used for any other oral drug rather than assuming LDN is exempt from that general caution.

What monitoring looks like in practice

For a patient with Hashimoto thyroiditis-related hypothyroidism who is starting LDN while on a stable levothyroxine dose, a reasonable baseline includes a current TSH with reflex free T4 and, where relevant to the reason LDN was started, a thyroid peroxidase antibody titer. Rechecking TSH and free T4 roughly 6 to 8 weeks after starting LDN follows standard practice for any new variable that could plausibly affect thyroid status, though no interaction-specific guideline sets this interval for the LDN-levothyroxine combination specifically.

If TSH falls below the lower reference limit, the standard endocrinology approach is a small levothyroxine dose reduction followed by a repeat TSH in another 6 to 8 weeks, rather than stopping levothyroxine outright. Hashimoto thyroiditis causes structural gland damage that does not reverse; LDN's proposed effect, if real, would be on ongoing inflammation, not on restoring destroyed thyroid tissue. Patients should not adjust their own levothyroxine dose based on symptoms alone, since symptoms of both under- and over-replacement can overlap or be nonspecific.

Other interactions in the LDN profile worth knowing

Opioid analgesics are the interaction that carries genuine, immediate risk: naltrexone at any dose will block or reverse the effect of opioid agonists such as oxycodone, tramadol, codeine, or buprenorphine, and this combination should be avoided rather than monitored. Concurrent use of immunosuppressive therapies (methotrexate, azathioprine, biologics) alongside LDN has not been formally studied for interaction risk; patients transitioning between these therapies should have that transition planned with the prescriber managing the underlying autoimmune condition. Naltrexone itself has no recognized absorption interactions, since its own oral absorption is rapid and largely complete regardless of food or co-administered drugs.

Special situations

Patients whose hypothyroidism is due to thyroid surgery, radioactive iodine ablation, or congenital absence of the gland have no remaining thyroid tissue for LDN to act on indirectly, so the autoimmune-modulation concern described above does not apply to them. The only remaining consideration in that group is the general levothyroxine timing practice described above, unrelated to LDN specifically.

Postmenopausal women are a population where even mild, sustained TSH suppression carries recognized risks to bone density, and clinicians managing this combination in that group should treat any TSH drift below the normal range as clinically meaningful rather than incidental.

Patients using compounded LDN should confirm the pharmacy is appropriately accredited (for example, PCAB accreditation) since compounded products are not FDA-approved and formulation quality varies by pharmacy; this is a general compounding-quality consideration rather than a specific levothyroxine interaction.

When to seek urgent care

New palpitations, chest pain, significant tremor, or unexplained rapid weight loss after starting LDN in a patient on levothyroxine warrants prompt evaluation rather than waiting for a scheduled lab recheck, since these can signal iatrogenic hyperthyroidism. Similarly, any sign of opioid withdrawal or loss of pain control in a patient who has separately taken an opioid medication while on naltrexone (at any dose) needs urgent attention, since naltrexone can precipitate withdrawal in opioid-dependent patients.

Evidence boundary

Established: naltrexone and levothyroxine have no shared metabolic or transporter pathway, and naltrexone is contraindicated with opioid agonists at any dose. Plausible but unproven: LDN's immune-modulating mechanism may reduce autoimmune thyroid activity and lower levothyroxine requirements in some patients with Hashimoto thyroiditis over a period of months. Not established: any specific rate, magnitude, or timeline for that effect, and any direct absorption interaction between LDN and levothyroxine. Readers and prescribers should treat numeric claims about thyroid antibody reduction or dose-adjustment frequency from small pilot studies as needing direct verification against the original paper before being used in clinical counseling.